利伐沙班片的主治功效

(Rivaroxaban) is a common anticoagulant drug that has been widely used in the prevention and treatment of hip (or knee) joint replacement surgery, deep vein thrombosis, pulmonary embolism, valvular atrial fibrillation and other diseases. It can inhibit factor Because the pharmacokinetic mechanism of rivaroxaban is clear, there is no need to adjust the dose based on laboratory indicators during clinical use, which may lead to undertreatment or overdose.

Rivaroxaban (Xarelto) achieves its anticoagulant effect mainly by inhibiting free and bound factor Xa and inhibiting the generation of thrombin through reversible competition with its active site. Rivaroxaban is rapidly absorbed after oral administration and reaches the maximum drug concentration (Cmax) in 2 to 4 hours. It is almost completely absorbed after oral administration and is not affected by food. The oral administration time of 10 mg tablets is not limited by meal times, while 20 mg tablets must be taken with food to achieve higher bioavailability. The half-life is 5 to 13 hours, which is shorter than warfarin. Therefore, when bleeding is suspected to be caused by drug overdose, it can be quickly corrected after stopping the drug.

The absorption of rivaroxaban depends on the site of drug release in the gastrointestinal tract, and administration of rivaroxaban in the distal stomach should be avoided. Because the renal clearance rate of elderly patients is slightly lower, the plasma concentration of rivaroxaban in elderly patients is higher than that in younger patients, and the half-life of the drug is longer, which is 11 to 13 hours.

Relevant foreign studies have shown that the area under the receiver operating characteristic curve (AUC) and Cmax of rivaroxaban are dose-dependent, and subjects did not experience accumulation effects at any dose, indicating that it has high safety and tolerability in a large dose range in healthy people. In this regard, patients can purchase and use this medicine with confidence.

Recommended hot articles: /newsDetail/73180.html